Bluebird Bio, Inc. (BLUE)
| Market Cap | 523.66M |
| Revenue (ttm) | -13.14M |
| Net Income (ttm) | -594.16M |
| Shares Out | 77.12M |
| EPS (ttm) | -10.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,469,487 |
| Open | 6.24 |
| Previous Close | 6.13 |
| Day's Range | 6.24 - 6.79 |
| 52-Week Range | 2.87 - 17.85 |
| Beta | 1.16 |
| Analysts | Hold |
| Price Target | 7.93 (+16.8%) |
| Earnings Date | Nov 3, 2022 |
About BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BLUE stock is "Hold." The 12-month stock price forecast is 7.93, which is an increase of 16.79% from the latest price.
News
Should You Buy the Dip With Bluebird Bio?
The near term looks good, but the long term might not.
bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.
World's Most Expensive Drugs Can't Cure What Ails This Biotech
Bluebird Bio has received a lot of attention for pricing two FDA-approved gene therapies at around $3 million annually, but its financial future remains uncertain.
Why Bluebird Bio Stock Is Taking Flight Today
The biotech stands out as a possible buyout target.
Is This Growth Stock Undervalued?
This biotech has made tremendous progress recently.
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?
Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2 Small Caps for Growth-Focused Investors
Investors seeking opportunities among growth stocks could be interested in the following small caps, as they represent companies whose trailing 12-month net income per share has improved significantly o...
Why Shares of Bluebird Bio Jumped 15.7% on Tuesday
Investors, prodded by analysts, warmed up to the company after another FDA-approved therapy.
bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD
bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.
Bluebird Bio stock falls after FDA approves gene therapy
Yahoo Finance's Brad Smith and Julie Hyman discusses the reversal in Bluebird Bio shares after the FDA approved its second gene therapy.
Bluebird Bio (BLUE) Stock Is in Focus Following FDA Approval
Shares of Bluebird Bio (NASDAQ: BLUE ) were trending higher today in premarket trading on news that the U.S. Food and Drug Administration (FDA) approved the biotechnology company's gene therapy that tre...
Bluebird Bio Stock Soars on FDA Approval of Gene Therapy for Rare Neurological Disease
The company anticipates the product to be available by the end of 2022.
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystro...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), ...
2 Risky Stocks That Are Running Low on Cash
Is it worth taking a chance on these stocks?
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that Jason Cole, Chief Strategy and Financial Officer, plans to leave bluebird bio to pursue new career opportunitie...
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
Think twice before investing in these companies.
Avoid Buying the Dip With These 2 Stocks During the Nasdaq Bear Market
Both are facing significant challenges that might get worse before they get better.
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
Biotech stocks are scorching right now. But the best of the best have strong gains.
bluebird bio Announces September Investor Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2022 Wells Farg...
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
Should You Buy This Growth Stock Following a Major Approval?
This biotech really needed some good news.
Why Bluebird Bio's Stock Dived by Over 11% This Week
Analysts were lukewarm on the seemingly very positive news reported by the company midweek.
BLUE Stock Moves as FDA Approves Bluebird Bio's Gene Therapy
Source: rafapress / Shutterstock Bluebird Bio (NASDAQ: BLUE ) stock is on the move Thursday following U.S. Food and Drug Administration (FDA) approval for ZYNTEGLO. ZYNTEGLO is a gene therapy designed f...
bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia
bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.